Economic evaluation of a weekly administration of a sustained-release injection of recombinant human growth hormone for the treatment of children with growth hormone deficiency |
Kang, Hye-Young
(Graduate School of Public Health, Institute of Health Services Research, Yonsei University)
Kim, Duk Hee (Department of Pediatrics, Severance Children's Hospital, Yonsei University) Yang, Sei-Won (Department of Pediatrics, College of Medicine, Seoul National University) Kim, Yoon-Nam (Graduate School of Public Health, Yonsei University) Kim, Miseon (Graduate School of Public Health, Yonsei University) |
1 | Yang SW. Management of children with short stature. J Korean Endocr Soc 2003;18:561-70 |
2 | Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM. A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metab 2002;15 Suppl 2:715-22 |
3 | Chiarelli F, Veimo D, Tauber M, Langham S, Dumas H, Johansson L, et al. Observations of non-adherence to recombinant human growth hormone therapy in clinical practice. Clin Ther 2008;30:307-16 DOI ScienceOn |
4 | Jnsson B, Mavros P, Gerth WC, Kong SX, Eichler H. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28 DOI ScienceOn |
5 | Torrance GW, SiggelJE, Luce BR. Framing and designing the cost-effectiveness analysis. In: Gold MR, Seigel JE, Ressell LB, Weinstein MC, eds., Cost-effectiveness in health and medicine. Oxford, New York. Oxford University Press, 1996: 54 |
6 | Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value in Health 2004;7:518-28 DOI ScienceOn |
7 | Grumbach MM. Growth hormone therapy and the short end of the stick. N Eng J Med 1988;319:238-41 DOI PUBMED ScienceOn |
8 | Lim SJ, Kang HY, Kang YJ, Lee BS, Park HM, Shin DH. Measuring utility for menopausal systems based on time trade-off and visual analogue scale methods. Korean J of Health Policy & Administration 2007;17:113-33 DOI ScienceOn |
9 | Ferris DG, Miller MD. Measurement of subjective phenomena in primary care research: the Visual Analogue Scale. The Fam Pract Res J 1993;13:15-24 PUBMED |
10 | Khan ZM, Keskinaslan A, Benedict A, Brixner D, Muszbek N. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008;62:338-51 DOI PUBMED ScienceOn |
11 | Bakker B, Rosenfeld RG. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 2008;14:143-54 DOI ScienceOn |
12 | Philip BK. Parametric statistics for evaluation of the visual analog scale. Anesth Analg 1990;71:710 DOI ScienceOn |
13 | Lee BC, Ko CW, Kim DH, Yang SW, Yoo HW, Chung WY. Clinical effects of E cole derived authentic recombinant human growth hormone(DA-3002) in children with growth hormone deficiency. J Korean Endocr Soc 1998;13:526-35 |
14 | Kim YI, Kim ES, Son JG. Human growth hormone. Seoul: Korea Institute of Science and Technology Information, 2002 |
15 | Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Ch 6. Cost-Utility Analysis. In: Methods for the economic evaluation of health care programmes. 3rd ed. New York. Oxford University Press, 2005b:151-3 |
16 | Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Ch 6. Cost-Utility Analysis. In: Methods for the economic evaluation of health care programmes. 3rd ed. New York. Oxford University Press, 2005a:147 |
17 | LG Life Science. An open-label, active controlled, randomized, parallel-group, multi-centre study to assess efficacy and safety after 6 months-administration of SR-hGH (sustained-release human growth hormone) 0.5 mg/kg/wk and Eutropin inj.(immediate-release human growth hormone) 0.21 mg/kg/wk to improve the growth failure in pre- pubertal children with growth hormone deficiency. 2007 |
18 | World Health Organization. Choosing interventions that are cost effective (WHO-CHOICE). available at: http://www. who.int/choice/costs/CER_thresholds/en/index.html. accessed on Dec. 18, 2008 |
19 | Won JK, Markowski DJ, Sclar DA, Skaer TL. Utility of a sustained-release formulation for antihypertensive therapy. J Hum Hypertens 1993;7:519-22 PUBMED ScienceOn |